Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients

Trial Profile

Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Albumin-granulocyte colony-stimulating factor fusion protein (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Granulocyte colony-stimulating factors
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Tianjin SinoBiotech
  • Most Recent Events

    • 16 Jul 2017 Status changed from recruiting to completed.
    • 03 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 03 Nov 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top